Baird analyst Andrew Wittmann maintains MasTec (NYSE:MTZ) with a Outperform and raises the price target from $111 to $120.
AN2 Therapeutics Provides Update On Epetraborole Ex-U.S. Development Plan In Treatment-Refractory MAC Lung Disease
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients
Treatment-Refractory MAC Lung Disease Clinical Development Strategy to
